Research progress of tertiary lymphoid structure in prognosis and immunotherapy of esophageal squamous cell carcinoma_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

NIU Zhenyi ¹ , JIN Runsen ¹ , YAN Kepeng ² , ZHANG Yan ² ,  LI Hecheng ¹

1. Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, P. R. China;
2. Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, P. R. China;

Corresponding?author：

LI Hecheng, Email: lihecheng2000@hotmail.com

Keywords：

Esophageal squamous cell carcinoma; tertiary lymphoid structure; immunotherapy; tumor immune microenvironment; immune checkpoint inhibitors; antitumor immune response; prognosis

DOI：

10.7507/1007-4848.202403018

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Esophageal squamous cell carcinoma is the main histological type of esophageal cancer in China, which seriously threatens the health of people. The application of immunotherapy, mainly immune checkpoint inhibitors, has greatly improved the prognosis of patients with esophageal squamous cell carcinoma, but the efficacy of treatment is still limited. Tertiary lymphoid structure (TLS) is an ectopic organized lymphoid structure that accumulates in non-lymphoid organs. Previous studies have found that TLS in esophageal squamous cell carcinoma is associated with better patient outcomes and enhanced immunotherapy efficacy. Based on current researches about TLS in esophageal squamous cell carcinoma, this paper reviews the relationship between TLS and the prognosis and immunotherapy of patients. We hope to provide reference for the precise immunotherapy of esophageal squamous cell carcinoma.

Citation： NIU Zhenyi, JIN Runsen, YAN Kepeng, ZHANG Yan, LI Hecheng. Research progress of tertiary lymphoid structure in prognosis and immunotherapy of esophageal squamous cell carcinoma. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2026, 33(3): 468-474. doi: 10.7507/1007-4848.202403018 Copy

1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.	Kallies A, Zehn D, Utzschneider DT. Precursor exhausted T cells: key to successful immunotherapy? Nat Rev Immunol, 2020, 20(2): 128-136.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.

1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52. Kallies A, Zehn D, Utzschneider DT. Precursor exhausted T cells: key to successful immunotherapy? Nat Rev Immunol, 2020, 20(2): 128-136.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Research progress of tertiary lymphoid structure in prognosis and immunotherapy of esophageal squamous cell carcinoma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content